Protocol Ledger

NCT05850689 · Phase III · RECRUITING

Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Interventional Phase III clinical trial protocol NCT05850689 sponsored by Intra-Cellular Therapies in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-05-02 Enrollment: 470 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05850689
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)470 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05850689
Protocol FieldVerified Registry Value
NCT IdentifierNCT05850689
Consolidated Lead SponsorIntra-Cellular Therapies
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment470 participants (ESTIMATED)
Registered Start Date2023-05-02
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI